**CASE REPORT**

**T790M mutation in stage IV EGFR-mutated NSCLC patient with acquired resistance reverted to original 19Del mutation after administration of a series of precision treatments: a case report**

Jialong Han¹,§, Ya Wang¹,§, Lili Zhong¹, Huijie Zhou¹, Min Yu², Yanying Li², You Lu², Yan Wang³,* and Jiang Zhu²,*

¹West China Hospital and West China Medical Center of Sichuan University, ²Department of Thoracic Oncology, West China Hospital, Sichaun University, and ³Department of IVF, West China Second Hospital, Sichuan University

*Correspondence: Yan Wang, wangyy1210@163.com; Jiang Zhu, hxnadal@163.com

**Abstract**

Existing studies have yet to elucidate clearly the mechanisms of secondary resistance to third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), neither is there any established standard therapy for patients resistant to third generation EGFR-TKIs. This case report demonstrates a rare mutation pattern in a male patient with a pathologic diagnosis of non-small cell lung cancer (NSCLC) harboring an EGFR exon 19 deletion (19Del) mutation, who then acquired an EGFR-T790M mutation after developing resistance to the first generation EGFR-TKI (gefitinib). The mutation reverted to the original EGFR-19Del mutation after the patient developed secondary resistance against the third generation TKI (osimertinib). This patient eventually achieved partial response (PR) with second generation TKI (afatinib) as a fourth-line treatment.

**Key words:** NSCLC; EGFR mutation; acquired resistance; driver gene

**Introduction**

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are promising in treatment of patients with non-small-cell lung cancer (NSCLC) harboring sensitive EGFR mutations. Response rate to first generation EGFR-TKIs gefitinib and erlotinib has been reported as 71% and 58%, respectively, in some “sensitive” patients who were previously confirmed to harbor EGFR mutations.¹,²
Despite an initial treatment response to EGFR-TKI, most of these patients inevitably acquire resistance after a progression-free period of about 10 months. Development of the EGFR-T790M mutation is the main mechanism of resistance against the first and second generation EGFR-TKIs, and Matsuo et al. demonstrate that T790M mutation frequency is linked to duration of first/second-line treatment in patients with exon 19 deletion. After approval by the Food and Drug Administration (FDA) for patients with EGFR-T790M mutation suffering disease progression during or after EGFR-TKI treatment, osimertinib (Tagrisso™) showed an overall response rate of about 73%, and a longer progression-free survival (PFS) of 13.8 months. Nonetheless, relapse occurred 9-13 months after a progression-free period of about 10 months. A genetic test using plasma was conducted on 22 February 2017 confirming a EGFR-T790M (NM-005228.3(EGFR):c.2369C>T(p.Thr790Met)) mutation, after which a third generation TKI, osimertinib, was given to the patient on 26 February 2017.

The patient then complained of cough again in January 2017; a follow-up chest CT scan showed further growth of tumor, which referred to an increase in the size of the primary lesion (dorsal segment of the lower lobe of the right lung). A genetic test using plasma was conducted on 22 February 2017 confirming a EGFR-T790M (NM-005228.3(EGFR):c.2369C>T(p.Thr790Met)) mutation, after which a third generation TKI, osimertinib, was given to the patient on 26 February 2017.

On 30 June 2017, a CT review scan confirmed the growth of the lesions. A biopsy was conveyed and pathologically resulted in adenocarcinoma and gene detection confirmed EGFR-19Del (NM-00522.3(EGFR):c.2236-2250del(p.Glu746-Ala750del)) mutation on 10 July 2017. A PET/CT follow-up review on 14 July 2017 also confirmed growth of the lesion in the dorsal segment of the lower lobe of the right lung, ipsilateral hilum and mediastinum lymph nodes, and the ipsilatera pleura (no new symptoms were reported). As the disease continued to progress despite administration of osimertinib, the patient accepted further treatment consisting of four cycles of chemotherapy of pemetrexed combined with cisplatin plus bevacizumab (Avastin™), specifically pemetrexed 930 mg d1; cisplatin 50 mg d1; 40 mg d2-3, bevacizumab 500 mg d1, 21 days repeated from 24 June 2017 to 30 September 2017, and two cycles of maintenance therapy with pemetrexed plus bevacizumab (pemetrexed 930 mg d1; bevacizumab 500 mg d1, 21 days repeated) from 26 October 2017 to 22 November 2017. Stable disease was confirmed after the four cycles of chemotherapy, with a slight reduction in the size of the lesion in the dorsal segment of the lower lobe of the right lung. However, the disease status reverted to progressive disease after two further cycles of maintenance therapy with pemetrexed plus bevacizumab, whereby the CT scan on 5 December 2017 confirmed a tumor (3.2×2.1cm) in the dorsal segment of the lower lobe of the right lung (the primary lesion) and a massive pleural effusion in the right chest.

After a genetic test using tissues was conducted, an EGFR-19Del (NM-00522.3(EGFR):c.2236-2250del(p.Glu746-
Ala750del)) mutation (with an abundance of 78.91%) and a MET mutation and the amplification of FGFR1, ALK, ERBB2, NTRK1, DDR2, BRCA1, SMO, ROS1, etc., were confirmed on 23 December 2017. The patient accepted and started treatment with second generation TKI (afatinib, Gilotrif™) plus bevacizumab (500 mg d1, 21 days repeated) from 14 December 2017. A CT review scan confirmed a tumor (2.0×2.0 cm) in the dorsal segment of the lower lobe of the right lung and an obvious reduction of the pleural effusion; these improvements were evaluated as PR. The recent CT scan confirmed the PR response on 12 April 2018, with a PFS of afatinib treatment exceeding 6 months till this report had been drafted. The whole treatment course is presented in Fig. 1, a variation of the CT image is presented in Fig. 2, all the samples and sequencing results of each EGFR mutation test are presented in supplementary table 1.

Discussion

The T790M-EGFR mutation is a common mutation following resistance to first generation TKIs, with an incidence of about 50-60%5,14; subsequent mutations after secondary resistance are varied.10 This case documents a rare mutation pattern where the main driver gene reverted to the original 19Del-EGFR mutation after developing resistance against third generation TKI. The patient was confirmed to have the exact same mutation as the original (NM-00522.3(EGFR):c.2236-2250del(p.Glu746-Ala750del), after receiving third-line treatment

![Figure 2. CT scan and response evaluation of the four lines of treatment. Line 1 and Line 3: mediastinal window; Line 2 and Line 4: lung window.](image-url)
with chemotherapy following development of secondary resistance against third generation TKI. Although new mutations appeared in the last genetic test, the main driver was still the original mutation. The possible mechanisms of resistance against osimertinib include both EGFR-dependent and EGFR-independent resistance mechanisms,5–13 but the mutation switching back to the original 19Del mutation is not included.

Given that the abundance of the EGFR-19Del mutation was confirmed to be 0.33% in plasma and 78.91% in tissue before and after chemotherapy, respectively, we were unable to determine whether chemotherapy had contributed to the increase in the observed frequency of the EGFR-19Del mutation. Further studies are required to illustrate the role of chemotherapy or antiangiogenic drugs in the modulation of mutation change.

The first-, second-, and third-line treatments for this patient were prescribed according to the guideline. Stable disease was achieved following third-line chemotherapy treatment with pemetrexed combined with cisplatin plus bevacizumab, after the patient developed secondary resistance to third generation TKI. Unfortunately, the disease continued to progress despite two further cycles of maintenance therapy with pemetrexed plus bevacizumab. After progressive disease was reported, the patient received second generation TKIs (afatinib) plus bevacizumab as fourth-line treatment and finally achieved PR. This final treatment choice was made without explicit guidance from the existing guideline. This treatment decision successfully extended the PFS and overall survival of this patient with phase IV NSCLC. This case study demonstrates a possible novel treatment option that can be considered in future clinical practice and management of refractory lung cancer.

Aftatinib as a second generation TKI is an irreversible inhibitor of the EGFR and HER2 inhibitor, and was approved to be used in treatment of TKI-naive patients with NSCLC with sensitive EGFR mutation or patients with NSCLC progression after cisplatin-based chemotherapy.14 PR was obtained in this case following treatment with Aftatinib, possibly because of the sensitivity of the driver 19Del mutation, although the ERBB2 amplification might also contribute to the sensitivity.

### Conclusion

This case presents a patient with stage IV NSCLC harboring an EGFR 19Del mutation derived from a secondary T790M mutation, who responded to afatinib as fourth-line treatment. The possibility of the driver mutation gene reverting to the original mutation after a series of alterations is indicated. This case illustrates that therapy targeting the main driver gene may make response to treatment more likely when the mutation varies through several lines of treatment. It may also warrant genetic re-testing during treatment into routine review when faced with disease progression or relapse.

### Acknowledgements

The authors thank all the ward staff who provided care to the patient and special thanks are given to the staff at Boehringer Ingelheim for their clinical consultation and editorial support.

### Supplementary data

Supplementary data are available at Precision Clinical Medicine Journal online.

### Funding

This work was supported by the National Natural Science Foundation of China (Grant No. 81673032).

### Conflict of interest statement

None declared.

### References

1. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947–57. doi:10.1056/NEJMoa0810699.
2. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239–46. doi:10.1016/S1470-2045(11)70393-X.
3. Janne PA. Challenges of detecting EGFR T790M in gefitinib/ erlotinib-resistant tumours. Lung Cancer 2008;60:S3–9. doi:10.1016/S0169-5002(08)00999-0.
4. Ma C, Wei S, Song Y. T790M and acquired resistance of EGFR TKI: a literature review of clinical reports. J Thorac Dis 2011;3:10–8. doi:10.3978/j.issn.2072-1439.2010.12.02.
5. Sequist LV, Wahlman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011;3:75ra26. doi:10.1126/scitranslmed.3002003.
6. Matsuo N, Azuma K, Sakai K, et al. Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients. Sci Rep 2016;6:36458. doi:10.1038/srep36458.
7. Cross DA, Ashton SE, Chiogrhii S, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 2014;4:1046–61. doi:10.1158/2159-8290.CD-14-0337.
8. Greig SL. Osimertinib: First Global Approval. Drugs 2016;76:263–73. doi:10.1007/s40265-015-0533-4.
9. Eberlein CA, Stetson D, Markovets AA, et al. Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models. Cancer Res 2015;75:2489–500. doi:10.1158/0008-5472.CAN-14-3167.
10. Ercan D, Choi HG, Yun CH, et al. EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors. Clin Cancer Res 2015;21:3913–23. doi:10.1158/1078-0432.CCR-14-2789.
11. Niederst MJ, Hu H, Mulvey HE, et al. The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies. Clin Cancer Res 2015;21:3924–33. doi:10.1158/1078-0432.CCR-15-0560.
12. Tang ZH, Lu JJ. Osimertinib resistance in non-small cell lung cancer: Mechanisms and therapeutic strategies. Cancer Lett 2018;420:242–6. doi:10.1016/j.canlet.2018.02.004.
13. Ortiz-Cuaran S, Scheffler M, Plenker D, et al. Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors. Clin Cancer Res 2016;22:4837–47.
14. Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 2013;19:2240–7. doi:10.1158/1078-0432.CCR-12-2246.
15. Park K, Tan EH, O’Byrne K, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2b, open-label, randomised controlled trial. Lancet Oncol 2016;17:577–89. doi:10.1016/S1470-2045(16)30033-X.